This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Etripamil
  • /
  • ReVeRA-201: Etripamil in Atrial Fibrillation, Phas...
Clinical trial

ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2

Read time: 1 mins
Last updated:25th Mar 2021
Status: Recruiting
Identifier: NCT04467905
ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2

Brief Summary:

Many patients experience persistent tachycardia with episodes of rapid ventricular rate despite chronic treatment to reduce ventricular rate. The objectives of this study are to demonstrate the superiority of a nasal spray of etripamil over placebo, in reducing ventricular rate in patients with atrial fibrillation; and to evaluate the safety and efficacy of etripamil Nasal Spray in patients with atrial fibrillation (AF).

Detailed Description:
This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of etripamil Nasal Spray in patients with atrial fibrillation (AF). This study includes Screening, the Treatment Period and Follow-up procedures.

Each subject will receive placebo or 70 mg of etripamil intranasally; treatment will be randomized in a 1:1 ratio, to yield 50 evaluable patients with atrial fibrillation in 2 groups of 25.

Patients with atrial fibrillation (AF) will be selected by the Investigator. The screening procedures will include a review of inclusion/exclusion criteria and recording of any concomitant medications.

After screening procedures are complete, eligible patients will be randomized to receive etripamil or placebo. Heart rate will be measured via Holter ECG (Electrocardiogram)10 minutes prior to and immediately before drug administration; patients must exhibit a rapid ventricular rate (≥110 bpm measured during 1 minute) prior to drug administration in order to be dosed. Blinded study drug will be administered during Holter ECG (Electrocardiogram) monitoring, which will be conducted for at least 10 minutes prior to and for 6 hours after administration.

Patients will undergo a safety follow-up assessment and return the Holter device approximately 24 hours post-dose. Patients will also be contacted by phone 7 days post-dosing for safety follow-up.

Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multi-Centre, Placebo-Controlled, Phase 2 Study of Etripamil Nasal Spray (NS) for the Reduction of Ventricular Rate in Patients With Atrial Fibrillation.
Actual Study Start Date: November 19, 2020
Estimated Primary Completion Date: August 2021
Estimated Study Completion Date: September 2021

- Placebo Comparator: Placebo
- Experimental: Etripamil

Category Value
Study type(s) Interventional
Estimated enrolment 80
Actual Study start date 19 November 2020
Estimated Study Completion Date 01 September 2021

View full details